Review

Effects of SARS-CoV-2 Vaccines on Sperm Quality: Systematic Review

Guanjian Li1,2*, MD, PhD; Rongqiu Zhang3,4*, MD; Bing Song1,2, MD, PhD; Chao Wang1,2, MD; Qunshan Shen5,6, MD, PhD; Xiaojin He7, MD, PhD; Yunxia Cao1,2, MD, PhD

1Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
2National Health Commission Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Hefei, China
3Reproductive Medicine Center, the Affiliated Jinyang Hospital of Guizhou Medical University, Guiyang, China
4The Second People's Hospital of Guiyang, Guiyang, China
5Reproductive Medicine Center, Human Sperm Bank, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
6Key Laboratory of Population Health Across Life Cycle, Ministry of Education of the People's Republic of China, Hefei, China
7Reproductive Medicine Center, Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

*these authors contributed equally

Corresponding Author:
Yunxia Cao, MD, PhD
Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University
No 81 Meishan Road
Hefei, 230022
China
Phone: 86 15395104659
Email: caoyunxia@126.com

Abstract

Background: The COVID-19 pandemic, caused by SARS-CoV-2, has triggered a global public health crisis of unprecedented proportions. SARS-CoV-2 vaccination is a highly effective strategy for preventing infections and severe COVID-19 outcomes. Although several studies have concluded that COVID-19 vaccines are unlikely to affect fertility, concerns have arisen regarding adverse events, including the potential impact on fertility; these concerns are plagued by limited and inconsistent evidence.

Objective: This review aims to provide a recent assessment of the literature on the impact of COVID-19 vaccines on male sperm quality. The possible impact of COVID-19 vaccines on fertility potential was also examined to draw a clearer picture and to evaluate the effects of COVID-19 on male reproductive health.

Methods: PubMed, Scopus, Web of Science, Embase, and Cochrane databases were searched from their inception to October 2023. Eligible studies included articles reporting SARS-CoV-2 vaccination and human semen quality and fertility, as well as the impact of vaccination on assisted reproductive technology treatment outcomes. The quality of cohort studies was assessed using the Newcastle-Ottawa Scale, and the quality of cross-sectional studies was assessed using the quality evaluation criteria recommended by the Agency for Healthcare Research and Quality. The systematic review followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.

Results: The initial literature search yielded 4691 records by searching 5 peer-reviewed databases (PubMed, Scopus, Web of Science, Embase, and Cochrane). Finally, 24 relevant studies were selected for our study. There were evident research inequalities at the regional level, with the United States and Western European countries contributing 38% (9/24) of the studies, Middle Eastern countries contributing 38% (9/24), China accounting for 21% (5/24), and Africa and South America accounting for none. Nonetheless, the overall quality of the included studies was generally good. Our results demonstrated that serious side effects of the COVID-19 vaccine are extremely rare, and men experience few problems with sperm parameters or reproductive potential after vaccination.

Conclusions: On the basis of the studies published so far, the COVID-19 vaccine is safe for male reproductive health. Obviously, vaccination is a wise option rather than experience serious adverse symptoms of viral infections. These instances of evidence
may help reduce vaccine hesitancy and increase vaccination coverage, particularly among reproductive-age couples. As new controlled trials and prospective cohort studies with larger sample sizes emerge, the possibility of a negative effect of the COVID-19 vaccine on sperm quality must be further clarified.

**KEYWORDS**
COVID-19 vaccine; SARS-CoV-2; reproductive system; fertility; sperm quality

**Introduction**

**Background**
The COVID-19 pandemic, caused by SARS-CoV-2, has severely affected global public health, economics, and social life since 2019 [1-3]. To establish herd immunity and effectively reduce the risk of COVID-19 infection, the medical and research community conducted many research studies within a short period to develop the SARS-CoV-2 vaccines. Impressively, these efforts have ultimately led to the development of multiple efficacious vaccines in a short period, which is an unprecedented and important accomplishment [4]. Vaccination is proven to be an effective tool for reducing the risk of infection and severe COVID-19 outcomes and is now a global priority [5,6].

Earlier reports have confirmed that the testis is one of the tissues with the highest expression of angiotensin-converting enzyme 2 messenger RNA (mRNA) and protein, both of which are key targets for SARS-CoV-2 to enter host cells [7]. The inflammatory state caused by COVID-19 may undermine the integrity of the blood-testis barrier and further promote the infiltration of the virus. Therefore, in the early stages of the COVID-19 epidemic, some researchers argued that the testes might be susceptible to SARS-CoV-2. In fact, a series of studies have confirmed a short-term reduction in testosterone production and semen quality in patients with COVID-19. Semen parameters, including semen volume, sperm concentration, total sperm count, total sperm motility, and progressive sperm motility, were negatively affected by SARS-CoV-2 infection [8,9]. On the basis of the aforementioned potential damage to the reproductive system following SARS-CoV-2 infection, some researchers suspected that vaccines that mimic the virus could also affect fertility via a similar mechanism. Numerous types of disinformation and misinformation have emerged on social media, including questioning the relationship between COVID-19 vaccination and male fertility [10-12]. This public fear is partly owing to a lack of understanding of the newly developed COVID-19 vaccine [13,14].

It is also important to note that the current authoritative evidence on the impact of COVID-19 vaccines on male fertility is still limited, and the results are controversial. The lack of evidence for a definitive conclusion could discourage the public, fuel concerns about the potential impact of the vaccine on male fertility, and lead to vaccine hesitancy [15-17].

**Objectives**
As the pandemic continues to evolve, the number of newly approved vaccines and scientific studies will continue to increase [18]. In this study, we systematically reviewed the latest data and theoretical considerations on the impact of COVID-19 vaccines on semen quality in men to provide more conclusive information for policy makers, health care providers, media, and the public.

**Methods**

**Search Strategy and Selection Criteria**

The search was restricted to articles on humans, published in any language, without additional restrictions. With regard to publication type, original studies were selected. Abstracts, comments, reviews (narrative or systematic), modeling only, case reports, case series (reporting data for <10 patients), and editorials were excluded. We evaluated the relevance and quality of the text. Two independent reviewers (GL and BS) screened all the studies by title, abstract, and keywords to identify potentially relevant articles. All articles obtained through the search strategy were imported into Rayyan (Qatar Computing Research Institute), and duplicates were removed. Papers that did not meet the inclusion criteria for the full-text evaluation were excluded. Subsequently, the full texts were screened to collect the data. Furthermore, the reference lists of the included studies were manually searched to identify additional eligible studies and to ensure that relevant studies were not missed.
Eligible studies that were chosen to be included in this study were those evaluating the impacts of the COVID-19 vaccine on semen quality and male reproduction. Articles related to female vaccination and those without information on male vaccination were excluded. Data on the effect of the SARS-CoV-2 on male fertility were also excluded. The inclusion and exclusion criteria are presented in Table 1. Any disagreements were resolved through discussion among the study team members. The flow and results of the literature search are summarized in a PRISMA flowchart (Figure 1). Ethics approval was not required for this study because the data were derived from previously published studies.

The initial literature search yielded 4691 records. Of these, 2204 duplicate articles were removed, 2249 records were further excluded based on title or abstract screening, and 214 were excluded based on full-text assessment. Finally, 24 studies were selected for evaluation. We extracted the data using a pretested data extraction form created in Microsoft Excel 2019 (Microsoft Corporation). Article information (e.g., PubMed Identifier, first author, year of publication, and country); study design; vaccine type; side effects; and changes in semen parameters were extracted from the articles.

Table 1. Summary of the inclusion and exclusion criteria.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article or study type</td>
<td>Population-based original research studies</td>
<td>Abstracts, comments, and editorials</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reviews and book chapters</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Protocols and modeling only</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Case reports and case series</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Animal experiment</td>
</tr>
<tr>
<td>Language</td>
<td>Any language</td>
<td>Without additional restrictions</td>
</tr>
<tr>
<td>Publication period</td>
<td>November 1, 2019, to October 1, 2023</td>
<td>All dates outside the span from November 2019 to October 2023</td>
</tr>
</tbody>
</table>
| Study content             | Studies assessing the impact of COVID-19 vaccines on semen quality and male reproduc-
|                           | tion                                                                              | Studies related to female vaccination without information on male vaccination       |
|                           |                                                                                    | Data on the effects of COVID-19 on male fertility                                 |

Figure 1. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart of the screening and selection process. WoS: Web of Science.
Characteristics of the Included Literature

The methodological quality of the included studies was evaluated according to study design. Cohort studies were assessed using the Newcastle-Ottawa Scale, which provides a score between 0 and 9 and assesses the following quality parameters: comparability of study groups, selection of study groups, and ascertainment of outcomes [19]. Cross-sectional studies were evaluated using 11 entries from the quality evaluation criteria recommended by the Agency for Healthcare Research and Quality [20]. Each entry contained options “Yes,” “No,” and “Unclear.” “Yes” was rated as 1 point, while “No” and “Unclear” were counted as 0. Scores of 0 to 3, 4 to 7, and 8 to 11 were considered as low-, medium- and high-quality studies, respectively.

Results

COVID-19 Vaccine Platform

Vaccines are critical and cost-effective tools to control the COVID-19 pandemic. Since the onset of the COVID-19 pandemic, research groups from various countries have made significant progress in developing vaccines in a short period using a variety of platform technologies, with >100 vaccine candidates currently undergoing preclinical development worldwide [21]. These vaccine platforms range from protein-based (eg, subunits and virus-like particles) and virus-based (eg, attenuated live and inactivated vaccines) strategies to gene-based strategies [22,23]. The different types of vaccine platforms are shown in Figure 2. In this study, we focused on several widely used vaccines that have been reported to affect semen quality.

Figure 2. Different platform types of COVID-19 vaccines and the possible mechanisms affecting semen quality. BTB: blood-testis barrier; mRNA: messenger RNA.

mRNA Vaccines

Several large biotechnology companies such as Pfizer, BioNTech, and Moderna have developed COVID-19 vaccines using advanced mRNA vaccine platforms. In the United States, the Food and Drug Administration approved emergency authorizations for the BNT162b2 (Pfizer-BioNTech) and mRNA - 1273 (Moderna) vaccines in December 2020 [24-26]. mRNA vaccines involve an innovative approach, borrowing the cell’s transcriptional machinery to produce the desired set of particles. Vaccine mRNA can enter cells and can be converted into SARS-CoV-2 glycoproteins (spike proteins). The spike proteins elicit an immune response by activating helper T and B cells, eventually establishing immunity against SARS-CoV-2 [27]. These mRNA-based vaccines are noninfectious. They do not contain any live viral particles and are synthesized by in vitro transcription in the absence of microbial molecules.

Recombinant Viral-Vectored Vaccines

Recombinant viral-vectored vaccines use a bioengineered viral vector that can express and clone antigens from the target pathogen [28]. Lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses are the common vectors used in this platform. Nonreplicating viral vaccines have been extensively studied and have a well-established track record for preventing infectious diseases because of their genetic malleability, safety, and ability to stimulate strong cellular immune responses without the use of adjuvants. Furthermore, a single dose of viral vector–based vaccines may provide adequate protection. Several COVID-19 vaccines based on recombinant viral vector technology including Sputnik V (Gamaleya Institute), ChAdOx1 (Oxford Astra Zeneca), and Ad26. COV2. S (Johnson & Johnson Janssen) have been approved for emergency use worldwide [29].

Inactivated Vaccines

Chemically or physically inactivated viral vaccines are among the oldest vaccine design approaches and have been used successfully against a variety of human viral infections such as hepatitis A, polio, and influenza [30]. This method involves injecting an inactivated virus into the host, inducing an immune response and promoting strong immunity against the virus. In contrast to their live attenuated counterparts, inactivated viral
vaccines pose few safety concerns and deliver a wide range of native viral antigens, including surface antigens with conserved epitope conformations, which can stimulate conformation-dependent antibody responses. As completely inactive viruses do not replicate, repeated administration and adjuvants are required to stimulate the immune system and ensure that these vaccines work properly [31]. Currently, several vaccines, including CoronaVac (Sinovac) and BBIBP-CorV (Sinopharm), are being widely used in several countries, including China.

**Effects of SARS-CoV-2 Vaccination on Semen Quality: Available Evidence**

All available COVID-19 vaccines had acceptable efficacy and safety profiles in phase 3 clinical trials [32]. As of January 2023, >13 billion doses of the vaccine had been administered worldwide, with an excellent safety and efficacy profile. However, as reproductive toxicity has not been evaluated in clinical trials, one reason for vaccine hesitancy is its potential negative effects on fertility [33].

As shown in Table 2, we identified 24 studies that evaluated the effects of different COVID-19 vaccines on semen quality (some studies simultaneously evaluated >1 vaccine). All the studies were published between March 2020 and October 2023.

The overall quality of both the cross-sectional and cohort studies is shown in Table 2.

All the studies were of reasonable quality. Of 24 studies, 9 (38%) studies were conducted in the United States and Western European countries [34-42], 5 (21%) in China [43-47], 1 (4%) in Indonesia [48], and 9 (38%) in the Middle Eastern countries [49-57]. In total, 3 (12%) studies used inactivated COVID-19 vaccines, 4 (17%) studies used viral-vectored vaccines, 8 (33%) studies used mRNA vaccines, and 3 (12%) studies included a combined analysis of multiple types of vaccines. A total of 11 (46%) studies involved patients with infertility undergoing ART, 11 (46%) involved healthy volunteers or sperm donors, and 2 (8%) involved other male populations with type 2 diabetes and nonserious chronic conditions. All studies described standard methods for sample collection and processing and followed the fifth edition of the World Health Organization laboratory manual. The study design, study population, vaccine type, result analysis, and adverse reaction reports of all 24 studies are listed in Table 3. These studies reported a variety of semen parameters: 9 (38%) reported total sperm count, 23 (96%) reported sperm concentration, 7 (29%) reported sperm morphology, 19 (79%) reported total sperm motility, 17 (71%) reported progressive sperm motility, and 11 (46%) reported total motile sperm count (TMSC).
Table 2. Summary of the inclusion and exclusion criteria.

<table>
<thead>
<tr>
<th>Source</th>
<th>Country</th>
<th>Study design</th>
<th>AHRQ\textsuperscript{a} or NOS\textsuperscript{b} score</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diaz et al [34], 2021-2022</td>
<td>United States</td>
<td>Prospective cross-sectional</td>
<td>6</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Gonzalez et al [35], 2020-2021</td>
<td>United States</td>
<td>Prospective cross-sectional</td>
<td>5</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Wang et al [43], 2021</td>
<td>China</td>
<td>Prospective cross-sectional</td>
<td>6</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Huang et al [44], 2021-2022</td>
<td>China</td>
<td>Retrospective cross-sectional</td>
<td>8</td>
<td>High quality</td>
</tr>
<tr>
<td>Zhu et al [45], 2020-2021</td>
<td>China</td>
<td>Retrospective cross-sectional</td>
<td>8</td>
<td>High quality</td>
</tr>
<tr>
<td>Xia et al [46], 2021</td>
<td>China</td>
<td>Retrospective cohort study</td>
<td>7</td>
<td>High quality</td>
</tr>
<tr>
<td>Dong et al [47], 2023</td>
<td>China</td>
<td>Retrospective cohort study</td>
<td>8</td>
<td>High quality</td>
</tr>
<tr>
<td>Abd et al [51], 2022</td>
<td>Iraq</td>
<td>Prospective cross-sectional</td>
<td>4</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Al-Alami et al [50], 2021</td>
<td>Jordan</td>
<td>Retrospective cohort study</td>
<td>5</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Alenzi et al [49], 2021</td>
<td>Saudi Arabia</td>
<td>Prospective cohort study</td>
<td>5</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Lestari et al [48], 2020-2022</td>
<td>Indonesia</td>
<td>Prospective cohort study</td>
<td>8</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Karavani et al [52], 2021-2022</td>
<td>Israel</td>
<td>Retrospective cross-sectional</td>
<td>7</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Gat et al [53], 2021-2022</td>
<td>Israel</td>
<td>Retrospective cross-sectional</td>
<td>7</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Lifshitz et al [54], 2021</td>
<td>Israel</td>
<td>Prospective cross-sectional</td>
<td>5</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Safrai et al [55], 2021</td>
<td>Israel</td>
<td>Retrospective cross-sectional</td>
<td>9</td>
<td>High quality</td>
</tr>
<tr>
<td>Barda et al [56], 2020-2021</td>
<td>Israel</td>
<td>Prospective cross-sectional</td>
<td>4</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Orvieto et al [57], 2021</td>
<td>Israel</td>
<td>Retrospective cohort study</td>
<td>6</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Olana et al [36], 2021</td>
<td>Italy</td>
<td>Prospective cross-sectional</td>
<td>8</td>
<td>High quality</td>
</tr>
<tr>
<td>Reschini et al [37], 2022</td>
<td>Italy</td>
<td>Retrospective cross-sectional</td>
<td>5</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Massarotti et al [38], 2021</td>
<td>Italy</td>
<td>Prospective cross-sectional</td>
<td>6</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Chillon et al [42], 2021</td>
<td>Germany</td>
<td>Retrospective cross-sectional</td>
<td>7</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Drapkina et al [39], 2021</td>
<td>Russia</td>
<td>Prospective cross-sectional</td>
<td>7</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Esaulenko et al [40], 2021</td>
<td>Russia</td>
<td>Prospective cross-sectional</td>
<td>7</td>
<td>Medium quality</td>
</tr>
<tr>
<td>Elagin et al [41], 2021-2022</td>
<td>Russia</td>
<td>Prospective cross-sectional</td>
<td>5</td>
<td>Medium quality</td>
</tr>
</tbody>
</table>

\textsuperscript{a}AHRQ: Agency for Healthcare Research and Quality.

\textsuperscript{b}NOS: Newcastle-Ottawa Scale.
Table 3. The effect of COVID-19 vaccines on semen parameters.

<table>
<thead>
<tr>
<th>Source</th>
<th>Country</th>
<th>Vaccine type</th>
<th>Sample size; population</th>
<th>Age (y)</th>
<th>Semen test before vaccination</th>
<th>Semen test after vaccination, days</th>
<th>Outcomes</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diaz et al [34], 2021-2022</td>
<td>United States</td>
<td>58% Moderna vaccines and 42% Pfizer vaccines</td>
<td>12; normal volunteers</td>
<td>Mean 26; range 25-30</td>
<td>Before the first dose of vaccine</td>
<td>T1: 3 months after the first dose and T2: at least 9 months after the second dose</td>
<td>No significant differences</td>
<td>Not reported</td>
</tr>
<tr>
<td>Gonzalez et al [35], 2020-2021</td>
<td>United States</td>
<td>21 received BNT162b2 and 24 received mRNA-1273</td>
<td>45; normal volunteers</td>
<td>Mean 28; range 25-31</td>
<td>Before the first dose of vaccine</td>
<td>75 (IQR 70-86) days after the second dose</td>
<td>After vaccination, the median sperm concentration, median TMSC, semen volume, and sperm motility were significantly increased</td>
<td>Not reported</td>
</tr>
<tr>
<td>Wang et al [43], 2021</td>
<td>China</td>
<td>Inactivated vaccine: CoronaVac (Sinovac)</td>
<td>153; patients with infertility undergoing IVF treatment</td>
<td>Mean 33; range 29-37</td>
<td>Before the first dose of vaccine</td>
<td>Median 71 (IQR 38-102) days after the second dose</td>
<td>After vaccination, the amount of semen increased, the vitality decreased, and the normal morphology of sperm decreased</td>
<td>Not reported</td>
</tr>
<tr>
<td>Huang et al [44], 2021-2022</td>
<td>China</td>
<td>Inactivated vaccine: BBIBP-CorV (Sinopharm) or CoronaVac (Sinovac)</td>
<td>128; men with previous semen examination in the medical center</td>
<td>Mean 31; range 29-35</td>
<td>Before the first dose of vaccine</td>
<td>Median 87.5 (IQR 52.0-137.5) days after the second dose</td>
<td>No significant differences</td>
<td>Not reported</td>
</tr>
<tr>
<td>Zhu et al [45] (2020-2021)</td>
<td>China</td>
<td>Inactivated vaccine</td>
<td>43; semen donors from sperm bank</td>
<td>Mean 28.6 (SD 5.9)</td>
<td>Before the first dose of vaccine</td>
<td>Median 9.1 (SD 8.1) days after the first dose</td>
<td>No significant differences</td>
<td>A sore arm for both the first and second injections (nearly 13.9% and 4.7%, respectively). One donor reported feeling tired</td>
</tr>
<tr>
<td>Xia et al [46], 2021</td>
<td>China</td>
<td>Inactivated vaccine: BBIBP-CorV (Sinopharm) or CoronaVac (Sinovac)</td>
<td>Vaccine group (n=105) and control group (n=155); patients undergoing IVF treatment</td>
<td>Vaccine group: mean 33.9 (SD 4.7) and control group: mean 33.3 (SD 4.4)</td>
<td>Not tested</td>
<td>Unvaccinated group and vaccinated group: average 80.6 days after the first dose</td>
<td>No significant differences</td>
<td>Pain at the injection site (11.43%), followed by fatigue (6.67%), headache (1.90%), nausea (0.95%), and low-grade fever (0.95%)</td>
</tr>
<tr>
<td>Dong et al [47], 2023</td>
<td>China</td>
<td>Inactivated vaccine</td>
<td>519; fertile men</td>
<td>Mean 35.3 (SD 4.3)</td>
<td>Not tested</td>
<td>Unvaccinated group and vaccinated group: ≤90 days or &gt;90 days after the first dose</td>
<td>No significant differences</td>
<td>The main adverse effect was injection site pain or redness; percentage of participants with fever (first dose: 0.3%, second dose: 0.6%, and booster dose: 1.9%)</td>
</tr>
<tr>
<td>Abd et al [51], 2022</td>
<td>Iraq</td>
<td>Pfizer-BioNTech (BNT162b2)</td>
<td>60; men undergoing IVF treatment (infertility due to clear female factors)</td>
<td>Mean 37.2 (SD 5.3)</td>
<td>Before the first dose of vaccine</td>
<td>Mean 101 (SD 37) days after the first dose</td>
<td>Both total motility and progressive motility were slightly reduced after vaccination</td>
<td>Not reported</td>
</tr>
<tr>
<td>Source</td>
<td>Country</td>
<td>Vaccine type</td>
<td>Sample size; population</td>
<td>Age (y)</td>
<td>Semen test before vaccination</td>
<td>Semen test after vaccination, days</td>
<td>Outcomes</td>
<td>Side effects</td>
</tr>
<tr>
<td>--------</td>
<td>---------</td>
<td>--------------</td>
<td>--------------------------</td>
<td>---------</td>
<td>------------------------------</td>
<td>----------------------------------</td>
<td>----------</td>
<td>--------------</td>
</tr>
<tr>
<td>Al-Alami et al [50], 2021</td>
<td>Jordan</td>
<td>Pfizer (44.1%), Sinopharm (31.4%), AstraZeneca (7.9%), and Moderna (0.3%)</td>
<td>354; participants who visited 1 infertility unit</td>
<td>Mean 35.6 (SD 7.9)</td>
<td>Not tested</td>
<td>Unvaccinated group and vaccinated group; clear data were not available</td>
<td>The sperm concentration was higher among vaccinated participants than unvaccinated participants</td>
<td>Not reported</td>
</tr>
<tr>
<td>Alenzi et al [49], 2021</td>
<td>Saudi Arabia</td>
<td>Pfizer-BioNTech (44%), Oxford and AstraZeneca (32%), and mixed (24%)</td>
<td>100; normal volunteers</td>
<td>Mean 37.89 (SD 10.3)</td>
<td>Before the first dose of vaccine</td>
<td>1 month after the second dose</td>
<td>There was a significant increase in progressive sperm motility: prevaccination motility: median 55.03 (IQR 42-61.75) vs postvaccination motility: median 56.5 (IQR 42.25-63)</td>
<td>Not reported</td>
</tr>
<tr>
<td>Lestari et al [48], 2020-2022</td>
<td>Indonesia</td>
<td>CoronaVac (Sinovac), AstraZeneca, and Moderna: proportion is not clear</td>
<td>70; patients with infertility</td>
<td>Vaccine group: mean 29.8 (SD 3.5) and control group: mean 29.3 (SD 4.5)</td>
<td>Before the first dose of vaccine</td>
<td>2 to 4 weeks after the second dose</td>
<td>The viral-vector vaccine caused a decrease in morphology as well as an increase in DFI</td>
<td>Not reported</td>
</tr>
<tr>
<td>Karavani et al [52], 2021-2022</td>
<td>Israel</td>
<td>Pfizer-BioNTech (BNT162b2)</td>
<td>58; men undergoing IVF treatment</td>
<td>Mean 38.0 (SD 6.1)</td>
<td>Before the first dose of vaccine</td>
<td>6 to 14 months after vaccination</td>
<td>No significant differences</td>
<td>Not reported</td>
</tr>
<tr>
<td>Gat et al [53], 2021-2022</td>
<td>Israel</td>
<td>Pfizer-BioNTech (BNT162b2)</td>
<td>37; semen donors from sperm banks</td>
<td>Mean 26.1 (SD 4.2)</td>
<td>Before the first dose of vaccine</td>
<td>T1, T2, and T3: included 1 to 3 semen samples per donor who provided the samples 15 to 45 days, 75 to 125 days, and &gt;145 days after vaccination</td>
<td>Compared with sperm concentration at T0, the concentration at T2 decreased by 15%, and total motor count decreased by 22%. Subsequently, T3 evaluation showed that the damage had recovered</td>
<td>Not reported</td>
</tr>
<tr>
<td>Lifshitz et al [54], 2021</td>
<td>Israel</td>
<td>Pfizer-BioNTech (BNT162b2)</td>
<td>75; normal volunteers, 40% of whom were medical staff</td>
<td>Mean 38.6 (SD 4.3)</td>
<td>Not tested</td>
<td>On average, 37 days after the second dose</td>
<td>Compared with the WHO reference range, there are only 2 borderline sperm specimens</td>
<td>Fatigue (34.7%), pain at the injection site (13.3%), fever (9.3%), and chills (8%)</td>
</tr>
<tr>
<td>Safrai et al [55], 2021</td>
<td>Israel</td>
<td>Pfizer-BioNTech (BNT162b2)</td>
<td>72; patients undergoing IVF treatment</td>
<td>Mean 35.7; range 33-43</td>
<td>Before the first dose of vaccine</td>
<td>Median 71.0 (IQR 40.5-104.8) days after the first dose</td>
<td>No significant differences</td>
<td>Not reported</td>
</tr>
<tr>
<td>Barda et al [56], 2020-2021</td>
<td>Israel</td>
<td>Pfizer-BioNTech (BNT162b2)</td>
<td>33; semen donors from sperm banks</td>
<td>27</td>
<td>Before the first dose of vaccine</td>
<td>The average sperm parameters of multiple samples were used for comparison. For each donor, at least 1 sample was received ≥72 days after the second dose</td>
<td>Total sperm count and TMSC increased after the second dose of vaccine</td>
<td>Pain at injection site: 79% (T1) and 88% (T2) of participants, lethargy: 9% (T1) and 48% (T2) of participants, and fever: 1 case (T1)</td>
</tr>
<tr>
<td>Source</td>
<td>Country</td>
<td>Vaccine type</td>
<td>Sample size; population</td>
<td>Age (y)</td>
<td>Semen test before vaccination</td>
<td>Semen test after vaccination, days</td>
<td>Outcomes</td>
<td>Side effects</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------</td>
<td>-----------------------------------</td>
<td>-------------------------</td>
<td>---------</td>
<td>-------------------------------</td>
<td>-----------------------------------</td>
<td>---------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Orvieto et al [57], 2021</td>
<td>Israel</td>
<td>Pfizer-BioN-Tech (BNT162b2)</td>
<td>36; patients with infertility undergoing IVF treatment</td>
<td>Mean 40.1 (SD 4.8)</td>
<td>Before the first dose of vaccine</td>
<td>Mean 33.3 (SD 14.9) days after the second dose</td>
<td>No significant differences</td>
<td>Not reported</td>
</tr>
<tr>
<td>Olana et al [36], 2021</td>
<td>Italy</td>
<td>Pfizer-BioN-Tech (BNT162b2)</td>
<td>47; normal volunteers</td>
<td>Mean 29.3 (SD 6.0)</td>
<td>Before the first dose of vaccine</td>
<td>Mean 70 days from the second dose</td>
<td>No significant differences</td>
<td>Not reported</td>
</tr>
<tr>
<td>Reschini et al [37], 2022</td>
<td>Italy</td>
<td>Pfizer-BioN-Tech (69%), Moderna (19%), Oxford and Astra Zeneca (9%), Johnson &amp; Johnson’s Janssen (1%), and mixed (2%)</td>
<td>106; fertile men undergoing ART² programs</td>
<td>Mean 39; range 36-42</td>
<td>Before the first dose of vaccine</td>
<td>Median 75 (IQR 38-112) days after the first dose</td>
<td>No significant differences</td>
<td>45% of the patients reported mild, self-resolving adverse events after the vaccine, including pain at injection site, fever, fatigue, nausea, muscle pain, and diarrhea</td>
</tr>
<tr>
<td>Massarotti et al [38], 2021</td>
<td>Italy</td>
<td>76% received mRNA vaccines, 20% viral-vector vaccines, 2% a mixed formulation, and 2% were not clear about the type</td>
<td>101; men undergoing fertility treatments</td>
<td>Mean 37.5 (SD 5.5)</td>
<td>Before the first dose of vaccine</td>
<td>Mean 2.3 (SD 1.5) months after the second dose</td>
<td>After vaccination, the median volume of the sample decreased from 3.0 to 2.6 ml. Sperm concentration, progressive motility, and TMSC increased</td>
<td>Not reported</td>
</tr>
<tr>
<td>Chillon et al [42], 2021</td>
<td>Germany</td>
<td>Pfizer-BioN-Tech (not reported)</td>
<td>86; normal volunteers</td>
<td>Vaccine group: mean 38 (SD 5.5) and control group: mean 36 (SD 6.5)</td>
<td>Not tested</td>
<td>Unvaccinated group and vaccinated group: clear data were not available</td>
<td>SARS-CoV-2 vaccination parameters and vaccine-induced antibodies were not associated with sperm parameters</td>
<td>Not reported</td>
</tr>
<tr>
<td>Drapkina et al [39], 2021</td>
<td>Russia</td>
<td>Viral-vector vaccine: Sputnik V</td>
<td>45; normal volunteers</td>
<td>Mean 36; range 30-44</td>
<td>Before the first dose of vaccine</td>
<td>Mean 90 days after the first dose</td>
<td>No significant differences</td>
<td>Not reported</td>
</tr>
<tr>
<td>Esauleenko et al [40], 2021</td>
<td>Russia</td>
<td>Viral-vector vaccine: Sputnik V</td>
<td>30; patients with type 2 diabetes</td>
<td>Mean 46; range 42-48</td>
<td>Before the first dose of vaccine</td>
<td>Mean 90 days after the first dose</td>
<td>No significant differences</td>
<td>19 (63%) patients demonstrated a temperature rise and 26 (87%) patients reported tenderness at injections site</td>
</tr>
</tbody>
</table>
Abd et al [51] observed that the total motility and progressive changes in sperm volume or motility were observed. Similarly, parameters were restored 145 days after vaccination, and no concentration and TMSC 75 to 125 days after vaccination, there was a selective decrease in sperm points, before and after immunization [53]. Compared with the prevaccination levels, there was a decrease in sperm quality. The study enrolled 72 individuals (57 of whom had normal sperm parameters). Sperm parameters in men with normal and abnormal sperm analysis did not change significantly after vaccination. The authors noted that after COVID-19 vaccination, none of the sperm parameters changed significantly [55]. In February and March 2021, Lifshitz et al [54] evaluated the effects of the Pfizer COVID-19 vaccine in 75 men with proven fertility [54]. The primary outcome was the percentage of abnormal sperm parameters in men 1 to 2 months after the second injection of the COVID-19 vaccine, including abnormal sperm morphology, reduced percentage of motile spermatozoa, and oligozoospermia rates. The results showed that the semen parameters after COVID-19 vaccination were mostly within the normal reference ranges established by the World Health Organization and did not indicate any causative negative effects of the COVID-19 vaccination. However, the participants in this study were a relatively homogeneous group, consisting of fertile male individuals from high socioeconomic groups. Moreover, participants were only followed up for 1 to 2 months after receiving the second dose of vaccine; therefore, long-term results have not yet been reported. In contrast, in a retrospective, longitudinal, multicenter study recently published in Andrology, the effects of the COVID-19 BNT162b2 vaccine on semen parameters were evaluated in 37 semen donors at different time points, before and after immunization [53]. Compared with the prevaccination levels, there was a selective decrease in sperm concentration and TMSC 75 to 125 days after vaccination (P=0.01 and P=0.007, respectively). Normal levels of these parameters were restored 145 days after vaccination, and no changes in sperm volume or motility were observed. Similarly, Abd et al [51] observed that the total motility and progressive sperm activity decreased significantly after BNT162b2 injection. Notably, considering that all semen parameters were still within the normal range, the investigator considered that the vaccine had no deleterious effects on semen parameters [51]. An additional prospective cohort study evaluated the effects of an inactivated vaccine (CoronaVac) on semen quality and in vitro fertilization (IVF) outcomes. A total of 542 patients undergoing IVF were divided into the unexposed group (nonvaccination) and the exposed group (vaccination), and it was found that the semen parameters seemed to fluctuate in the vaccinated men, including increased semen volume, decreased normal forms of sperm, and lower motility, whereas the motile sperm counts were similar. In addition, all semen parameters were above the lower reference limit. Therefore, researchers jointly believed that inactivated vaccines may not negatively affect sperm indicators or embryo development potential in men [43]. However, although this was a cohort study with a relatively large sample size, the male participants were all infertile, limiting the generalizability of the findings.

Surprisingly, significant improvements in some sperm parameters were noted after the COVID-19 vaccination. Massarotti et al [38] conducted a prospective study in which 101 vaccinated men (who were undergoing fertility treatments) had semen testing before vaccination and 2.3 (SD 1.5) months after the second dose of vaccine (76% of the participants were vaccinated with mRNA vaccine and 20% with viral-vectorized vaccine). The investigators found a significant reduction in the median volume of the sample (from 3.0 to 2.6 mL), whereas sperm concentration, progressive motility, and TMSC increased (from 25.0 to 43.0 million/mL, from 50% to 56%, and from 34.8 to 54.6 million, respectively) [38]. In another prospective cohort study published in JAMA, Gonzalez et al [35] evaluated the effect of mRNA vaccines in 45 healthy volunteers (21 Pfizer and 24 Moderna) and found no significant decrease in sperm parameters. Semen samples were collected before the first dose and a median of 75 days after the second dose [35]. The baseline median sperm concentration was 26 million/mL, and the TMSC was 36 million. After the second vaccine dose, the median sperm

### Discussion

#### Principal Findings

Safrai et al [55] published the first study on the impact of the COVID-19 vaccine on sperm parameters, demonstrating that the BNT162b2 mRNA vaccine (Pfizer or BioNTech) was not associated with a decrease in sperm quality. The study enrolled 72 individuals (57 of whom had normal sperm parameters). Sperm parameters in men with normal and abnormal sperm analysis did not change significantly after vaccination. The authors noted that after COVID-19 vaccination, none of the sperm parameters changed significantly [55]. In February and March 2021, Lifshitz et al [54] evaluated the effects of the Pfizer COVID-19 vaccine in 75 men with proven fertility [54]. The primary outcome was the percentage of abnormal sperm parameters in men 1 to 2 months after the second injection of the COVID-19 vaccine, including abnormal sperm morphology, reduced percentage of motile spermatozoa, and oligozoospermia rates. The results showed that the semen parameters after COVID-19 vaccination were mostly within the normal reference ranges established by the World Health Organization and did not indicate any causative negative effects of the COVID-19 vaccination. However, the participants in this study were a relatively homogeneous group, consisting of fertile male individuals from high socioeconomic groups. Moreover, participants were only followed up for 1 to 2 months after receiving the second dose of vaccine; therefore, long-term results have not yet been reported. In contrast, in a retrospective, longitudinal, multicenter study recently published in Andrology, the effects of the COVID-19 BNT162b2 vaccine on semen parameters were evaluated in 37 semen donors at different time points, before and after immunization [53]. Compared with the prevaccination levels, there was a selective decrease in sperm concentration and TMSC 75 to 125 days after vaccination (P=0.01 and P=0.007, respectively). Normal levels of these parameters were restored 145 days after vaccination, and no changes in sperm volume or motility were observed. Similarly, Abd et al [51] observed that the total motility and progressive sperm activity decreased significantly after BNT162b2 injection. Notably, considering that all semen parameters were still within the normal range, the investigator considered that the vaccine had no deleterious effects on semen parameters [51]. An additional prospective cohort study evaluated the effects of an inactivated vaccine (CoronaVac) on semen quality and in vitro fertilization (IVF) outcomes. A total of 542 patients undergoing IVF were divided into the unexposed group (nonvaccination) and the exposed group (vaccination), and it was found that the semen parameters seemed to fluctuate in the vaccinated men, including increased semen volume, decreased normal forms of sperm, and lower motility, whereas the motile sperm counts were similar. In addition, all semen parameters were above the lower reference limit. Therefore, researchers jointly believed that inactivated vaccines may not negatively affect sperm indicators or embryo development potential in men [43]. However, although this was a cohort study with a relatively large sample size, the male participants were all infertile, limiting the generalizability of the findings.

Surprisingly, significant improvements in some sperm parameters were noted after the COVID-19 vaccination. Massarotti et al [38] conducted a prospective study in which 101 vaccinated men (who were undergoing fertility treatments) had semen testing before vaccination and 2.3 (SD 1.5) months after the second dose of vaccine (76% of the participants were vaccinated with mRNA vaccine and 20% with viral-vectorized vaccine). The investigators found a significant reduction in the median volume of the sample (from 3.0 to 2.6 mL), whereas sperm concentration, progressive motility, and TMSC increased (from 25.0 to 43.0 million/mL, from 50% to 56%, and from 34.8 to 54.6 million, respectively) [38]. In another prospective cohort study published in JAMA, Gonzalez et al [35] evaluated the effect of mRNA vaccines in 45 healthy volunteers (21 Pfizer and 24 Moderna) and found no significant decrease in sperm parameters. Semen samples were collected before the first dose and a median of 75 days after the second dose [35]. The baseline median sperm concentration was 26 million/mL, and the TMSC was 36 million. After the second vaccine dose, the median sperm

---

**Table:**

<table>
<thead>
<tr>
<th>Source</th>
<th>Country</th>
<th>Vaccine type</th>
<th>Sample size; population</th>
<th>Age (y)</th>
<th>Semen test before vaccination</th>
<th>Semen test after vaccination, days</th>
<th>Outcomes</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elagin et al [41], 2021-2022</td>
<td>Russia</td>
<td>Viral-vector vaccine: (Sputnik V)</td>
<td>44; normal volunteers</td>
<td>Mean 22.4 (SD 4.7)</td>
<td>Before the first dose of vaccine</td>
<td>10-12 days after the first dose and 32-36 days after the second dose</td>
<td>No significant differences</td>
<td>A total of 5 and 7 participants exhibited fever with headache after the first and second vaccine doses, respectively</td>
</tr>
</tbody>
</table>

---

**Note:**

- T1: time point 1.
- T2: time point 2.
- TMSC: total motile sperm count.
- IVF: in vitro fertilization.
- DFI: DNA fragmentation index.
- T3: time point 3.
- T0: time point 0.
- WHO: World Health Organization.
- ART: assisted reproductive technology.
concentration increased to 30 million/mL, and the median TMSC concentration increased to 44 million. Sperm motility and semen volume also increased significantly. The authors suggested that the increase in sperm parameters might be explained by known individual variations in sperm and increased abstinence time before postvaccine sample collection. Similarly, Barda et al [56] evaluated the effect of 2 doses of the vaccine (BNT162b2) on the sperm parameters of 33 sperm donors who donated sperm on multiple occasions. Compared with the percentage of motile sperm in the sample before vaccination, the percentage after the second dose of the vaccine did not change. However, the total sperm and motile counts increased unexpectedly [56]. One possible explanation is that some participants changed their lifestyle habits or were more health conscious than the retrospectively enrolled infertile population, which acted as a confounding factor and positively affected sperm quality [58].

Two previous meta-analyses examined the effect of COVID-19 vaccination on sperm parameters based on published data [59,60]. Both studies suggested that the vaccination had no discernible negative impact on sperm quality. However, the 2 meta-analyses had nonnegligible limitations: the included studies used different types of vaccines, administered different doses of vaccines, had mostly unknown time intervals from vaccination to sperm analysis, had large differences in the participating populations, and had a small sample size for each group after the subgroup analysis. In other words, the methodological quality of meta-analyses assessing the impact of COVID-19 vaccination on semen parameters is currently unsatisfactory. As new controlled trials and prospective cohort studies with larger sample sizes emerge, the possibility of a negative effect of the COVID-19 vaccine on sperm quality must be further clarified.

Commonly reported side effects of the COVID-19 vaccine in premarketing clinical trials and postmarketing surveillance programs include systemic reactions (eg, fatigue, headache, and muscle pain) as well as injection site reactions (eg, pain, redness, and swelling), with rare serious adverse events [61,62]. Furthermore, fever is considered one of the most common side effects of vaccination [63]. According to the literature, fever can temporarily impair sperm parameters, causing a decline in sperm count, quality, and DNA integrity [64]. It should be noted that a range of studies have demonstrated fever to be a common adverse effect following multiple vaccine injections including mRNA vaccines (eg, BNT162b2), inactivated vaccines (eg, CoronaVac), and viral-vector vaccines (eg, Ad26, Sputnik V). Therefore, male patients who experience fever after receiving the COVID-19 vaccine may experience fluctuations in their sperm parameters. However, this effect is similar to that caused by fever due to other registered vaccines [41,47,54].

According to a study by Gat et al [53], the systemic immune response following BNT162b2 immunization may contribute to the deterioration of selective temporary sperm concentration and TMSC; however, the long-term prognosis remains favorable [53]. It is important to note that similar studies did not have data on the detailed health and immune status of the participants before vaccination. Therefore, their conclusions should be interpreted with caution. Carto et al [65] examined data from a large US electronic health record database on the risk of orchitis, epididymitis, or both in men vaccinated against COVID-19 [65]. They discovered that the serum levels of antisperm antibodies and antiphospholipid antibodies against cardiolipin, phosphatidylinerine, annexin V, and 2-glycoprotein-1 did not differ significantly before and after vaccination. Furthermore, the levels of these autoimmune antibodies did not correlate with the sperm parameters. Their findings even suggested that COVID-19 vaccination was linked to a lower risk of orchitis, epididymitis, or both (odds ratio 0.568, 95% CI 0.497-0.649). More directly, Chillon et al [42] examined antibody concentrations in the seminal plasma of 86 men vaccinated with the new Crown pneumonia vaccine and showed that the antibody levels in seminal plasma after COVID-19 vaccination were correlated with serum antibody titers, but not with sperm parameters.

In addition, BNT162b2 and mRNA-1273 are lipid nanoparticle-formulated vaccines against SARS-CoV-2. These excipients, adjuvants, or both may act as vehicles for therapeutic content delivery while also increasing the intensity of the immune response [22]. Several studies have shown that these nanoparticles can cross biological barriers and can be deposited in reproductive organs, such as the testes, impairing sperm quality by increasing inflammation, damaging DNA structure, decreasing mitochondrial function, and inducing apoptosis [66]. Therefore, some researchers are concerned that vaccine excipients, adjuvants, or both may induce testicular damage. However, Olana et al [36] found no significant differences in the levels of reactive oxygen metabolites, electrolytes, or interleukin-6 in the seminal plasma of participants before and after the BNT162b2 vaccination [36]. Indeed, the current basic research evidence and clinical data supporting the idea that a systemic immune response after COVID-19 vaccination can lead to impaired sperm quality are insufficient.

Although semen analysis serves as the foundation for evaluating male fertility, it should be noted that it is an imperfect predictor of fertility potential. Further persuasive evidence comes from ART and artificial insemination by partner outcomes in couples after receiving the COVID-19 vaccine [57,67]. In a prospective cohort study involving 735 infertile couples, Dong et al [47] demonstrated that the quality of the embryos and the pregnancy rate in IVF treatment were unaffected by the couples’ vaccination status or vaccine type. Similarly, no differences in fertility or pregnancy outcomes were observed in the study by Orvieto et al [57]. In another multicenter prospective study of 4185 couples, Wang et al [68] found no association between COVID-19 vaccination status (eg, inactivated, adenoviral, and recombinant vaccines) and pregnancy rates in artificial insemination by partner treatment [68].

More directly, using data from an internet-based preconception cohort study, Wesselinl et al [69] investigated the relationship between COVID-19 vaccination and SARS-CoV-2 infection with fertility in couples attempting spontaneous pregnancy [69]. Their results suggested that male SARS-CoV-2 infection may be associated with a short-term decline in fertility, whereas COVID-19 vaccination had no effect on fertility in either partner.

https://publichealth.jmir.org/2023/1/e48511 JMIR Public Health Surveill 2023 | vol. 9 | e48511 | p. 11 (page number not for citation purposes)
Limitations

It is important to acknowledge that this review has a few limitations. First, data from most relevant studies were observational and lacked complete follow-up and analysis of missing data. All the included studies assessed vaccination based on self-reports or with no descriptions. Although previous influenza vaccination validation studies found 97% agreement between self-report and medical records, the conclusion may not be directly generalizable to COVID-19 vaccination, and misclassification risk may still exist [70]. Second, there is a need for more robust studies, with more precise eligibility criteria, appropriate sample sizes, and a more representative population, not focusing only on specific groups, such as those undergoing IVF. Third, despite the transient alterations in sperm parameters found in some studies, these findings were often not well supported by histological or pathophysiological data. Furthermore, the potential implications for sperm biology, including mitochondrial function, and the possible effects on the regulatory systems of epigenetic changes have received little attention.

However, given the widespread and ongoing spread of COVID-19, the available data on decreased semen quality in survivors of COVID-19 outweigh concerns about the potential negative effects of the COVID-19 vaccine on sperm parameters [71,72]. From the perspective of reproduction, vaccination against COVID-19 is preferable for severe adverse symptoms of the SARS-CoV-2 infection. Large-scale prospective cohort studies and randomized controlled trials of existing COVID-19 vaccines and newly developed vaccines are needed to further confirm this review’s conclusion.

Conclusions

In summary, the data in this review show that the COVID-19 vaccine is safe for male reproductive health. Serious side effects of the COVID-19 vaccine are extremely rare, and men experience few problems with sperm parameters or reproductive potential after vaccination. Considering that SARS-CoV-2 infection itself may be associated with impaired fertility, vaccination could serve as a potential tool to preserve male fertility by preventing COVID-19. Therefore, vaccination should be clearly recommended for all men wishing to have children unless there are additional contraindications.

Acknowledgments

The authors would like to thank the researchers from Anhui Medical University. This work was supported by The National Natural Science Foundation of China (number 82201777), the Key Project of Natural Science Research in the Universities of Anhui Province (number KJ2021A0296), and Basic and Clinical Collaborative Research Program of Anhui Medical University (number 2022xkjT020). YX C, XJ H, QS S, CW, and BS should be considered equal contributors.

Data Availability

All data generated or analyzed during this study are included in this published paper (and its supplementary information files).

Conflicts of Interest

None declared.

Multimedia Appendix 1

Filled-in PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist. [DOCX File, 35 KB-Multimedia Appendix 1]

Multimedia Appendix 2

Search strategy in electronic databases. [DOCX File, 19 KB-Multimedia Appendix 2]

References


Abbreviations

- **ART**: assisted reproductive technology
- **IVF**: in vitro fertilization
- **mRNA**: messenger RNA
- **PRISMA**: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- **TMSC**: total motile sperm count

---

Edited by A Mavragani, T Sanchez; submitted 26.04.23; peer-reviewed by H Zhu, B Ma; comments to author 02.06.23; revised version received 06.06.23; accepted 31.10.23; published 06.12.23

Please cite as:


©Guanjian Li, Rongqiu Zhang, Bing Song, Chao Wang, Qunshan Shen, Xiaojin He, Yunxia Cao. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 06.12.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on https://publichealth.jmir.org, as well as this copyright and license information must be included.